RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

Author:

Sharma Ritesh,Pancholi Shyam

Abstract

RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditionsA simple, sensitive and precise RP-HPLC-DAD method was developed and validated for the determination of olmesartan medoxomil (AT-II receptor blocker) in the presence of its degradation products. Olmesartan medoxomil and all the degradation products were resolved on a C18column with the mobile phase composed of methanol, acetonitrile and water (60:15:25,V/V/V, pH 3.5 by orthophosphoric acid) at 260 nm using a photodiode array detector. The method was linear over the concentration range of 1-18 μg mL-1and precise with RSD < 1 % in intra- and inter-day study. Excellent recoveries of 99.3 ± 0.9 to 100.8 ± 1.2% proved the accuracy of the method. Developed method was specific, as indicated by chromatographic resolution > 2.0 for each peak and sensitive withLOD0.03 μg mL-1andLOQ0.1 μg mL-1. The method was used to study the drug degradation behavior under forced conditions. Four degradation products (DP-I, II, III, IV) were formed during the degradation study in 0.1 mol L-1HCl whereas only DP-I, II and III were formed in water, 0.01 mol L-1NaOH and 3% H2O2. No significant thermal or photolytic degradation was observed in solid drug. The method was applied successfully for the assay of olmesartan medoxomil in the tablet dosage form.

Publisher

Walter de Gruyter GmbH

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Reference18 articles.

1. FDA, Draft Guidance for Industry: Stability Testing of Drug Substances and Drug Products, FDA, Rockville 1998.

2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), Step 5, ICH Geneva, Aug. 2003.

3. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview;H. Brunner;J. Hum. Hypertens,2002

4. Olmesartan medoxomil, a novel potent angiotensin II blocker;H. Koike;Ann. Rep. Snakyo Res. Lab,2003

5. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker;D. Mire;J. Cardiovasc. Pharmacol,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3